These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 8952671)
1. [Economic contribution of mofetil mycofenolate as preventive immunosuppressive treatment after renal transplantation from cadaver]. Louis-Touizer C; Nuijten MJ; Bayle F; Cantarovich D; Lang P; Lebranchu Y; Le Pogamp P; Touraine JL; Vialtel P; Monroe T; de Vries MJ Presse Med; 1996 Nov; 25(33):1577-82. PubMed ID: 8952671 [TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation. Baker GM; Martin JE; Jang R; Schroeder TJ; Armitstead JA; Myre S; First MR Transplant Proc; 1998 Dec; 30(8):4082-4. PubMed ID: 9865304 [No Abstract] [Full Text] [Related]
3. One-year, single-center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation. Khosla UM; Martin JE; Baker GM; Schroeder TJ; First MR Transplant Proc; 1999; 31(1-2):274-5. PubMed ID: 10083105 [No Abstract] [Full Text] [Related]
4. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Sullivan SD; Garrison LP; Best JH J Am Soc Nephrol; 1997 Oct; 8(10):1592-8. PubMed ID: 9335389 [TBL] [Abstract][Full Text] [Related]
5. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients. Machnicki G; Ricci JF; Brennan DC; Schnitzler MA Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764 [TBL] [Abstract][Full Text] [Related]
6. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181 [TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation. Young M; Plosker GL Pharmacoeconomics; 2002; 20(10):675-713. PubMed ID: 12162756 [TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Remuzzi G; Lesti M; Gotti E; Ganeva M; Dimitrov BD; Ene-Iordache B; Gherardi G; Donati D; Salvadori M; Sandrini S; Valente U; Segoloni G; Mourad G; Federico S; Rigotti P; Sparacino V; Bosmans JL; Perico N; Ruggenenti P Lancet; 2004 Aug 7-13; 364(9433):503-12. PubMed ID: 15302193 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. Rousseau A; Laroche ML; Venisse N; Loichot-Roselmac C; Turcant A; Hoizey G; Compagnon P; Hary L; Debruyne D; Saivin S; Jacqz-Aigrain E; Buchler M; Villeneuve C; Vergnenègre A; Le Meur Y; Marquet P Transplantation; 2010 May; 89(10):1255-62. PubMed ID: 20224514 [TBL] [Abstract][Full Text] [Related]
10. Effect of new immunosuppressive regimens on cost of renal transplant maintenance immunosuppression. Gentil MA; González-Roncero F; Cantarell C; López M; Marco J Transplant Proc; 2005 Apr; 37(3):1441-2. PubMed ID: 15866631 [TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. Ross DJ; Waters PF; Levine M; Kramer M; Ruzevich S; Kass RM J Heart Lung Transplant; 1998 Aug; 17(8):768-74. PubMed ID: 9730425 [TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation. Annemans L; Lemkuhl H; Tenderich G; Schulz U; Yang XL; Ricci JF; Hetzer R Transplant Proc; 2007 Dec; 39(10):3306-12. PubMed ID: 18089377 [TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil versus azathioprine in organ transplantation. Cravedi P; Perna A; Ruggenenti P; Remuzzi G Am J Transplant; 2009 Dec; 9(12):2856-7. PubMed ID: 19845579 [No Abstract] [Full Text] [Related]
15. Improvement in long-term graft survival in cadaveric renal transplant recipients treated with mycophenolate mofetil. Hazzan M; Provot F; Glowacki F; Copin MC; Roumilhac D; Labalette M; Pruvot FR; Noel C Transpl Int; 2004 Oct; 17(9):525-30. PubMed ID: 15338120 [TBL] [Abstract][Full Text] [Related]
16. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Behrend M Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667 [TBL] [Abstract][Full Text] [Related]
17. Safe conversion of mycophenolate mofetil to azathioprine in kidney transplant recipients with sirolimus-based immunosuppression. El-Agroudy AE; El-Dahshan KF; Wafa EW; Sheashaa HA; Gad ZA; Ismail AM; Shokeir AA; Ghoneim MA Nephrology (Carlton); 2009 Apr; 14(2):255-61. PubMed ID: 19017277 [TBL] [Abstract][Full Text] [Related]
18. The cost effectiveness of mycophenolate mofetil in the first year after living related renal transplantation. Süleymanlar G; Tuncer M; Sarikaya M; Ersoy F; Aktan S; Yakupoğlu G; Karpuzoğlu T Transplant Proc; 2001 Aug; 33(5):2780-1. PubMed ID: 11498158 [No Abstract] [Full Text] [Related]